GlassScriptPhysician profile
Thomas D Regan
NPI 1073585907
$927.14
in general payments reported to CMS, 2019-2025
14 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.34 · 2020: $160 · 2021: $47.50 · 2022: $53.16 · 2023: $207 · 2024: $300 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $203.55 | 2020-2025 | Adbry |
| Janssen Biotech, INC. | $124.09 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $90.59 | 2019-2020 | |
| Amgen INC. | $81.18 | 2024 | Otezla |
| Prugen, INC. Pharmaceuticals | $66.63 | 2020 | |
| Arcutis Biotherapeutics, INC. | $65.41 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $56.98 | 2020-2023 | Taltz, Olumiant |
| Incyte Corporation | $52.80 | 2023-2025 | Opzelura |
| Abbvie INC. | $52.22 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $35.24 | 2020-2022 | |
| Teleflex LLC | $31.33 | 2023 | Manta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.60 | 2023 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2024 | Sotyktu |
| Genzyme Corporation | $18.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Regan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.